↓ Skip to main content

Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments

Overview of attention for article published in British Journal of Dermatology, July 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
1 news outlet
twitter
8 X users
facebook
1 Facebook page

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
21 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments
Published in
British Journal of Dermatology, July 2018
DOI 10.1111/bjd.16716
Pubmed ID
Authors

K. Boswell, H. Cameron, J. West, C. Fleming, S. Ibbotson, R. Dawe, J. Foerster

Abstract

Narrowband - UVB (NB-UVB) treatment for psoriasis is considered expensive. However, existing data are based on estimates and do not consider indirect cost savings. To define actual costs of NB-UVB incurred by the service provider, as well as treatment-associated cost savings. Data linkage of (i) comprehensive treatment records, (ii) prescribing data for all NB-UVB treatment episodes spanning six years in a population of 420,000. Minimisation of data fluctation by: (a) compiling data from 4 independent treatment sites, (b) use of drug prescribing unrelated to psoriasis as negative control. NHS Tayside spent an average of £257 per NB-UVB treatment course (£257 ± 63; range 150 - 286 across four independent treatment sites), contrasting sharply with the estimate of £1882 used by NICE UK. The cost of topical treatments averaged £128 per patient in the 12-months prior to NB-UVB, accounting for 42% of overall drug costs incurred by these patients. This was reduced by 40% to £53 per patient over the 12 month period following NB-UVB treatment while psoriasis unrelated drug-prescribing remained unchanged, suggesting disase-specific effects of NB-UVB. Data were not due to site-specific factors as confirmed by highly similar results observed between treatment sites operated by distinct staff. Finally, we detail all staff hours directly and indirectly involved in treatment, allowing direct translation of cost into other health care systems. NB-UVB is a low-cost treatment; cost figures currently used in health technology appraisals are an overestimate based on the data presented here. Creating or extending access to NB-UVB is likely to offer additional savings by delaying or avoiding costly third line treatments for many patients. This article is protected by copyright. All rights reserved.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 19%
Student > Doctoral Student 3 14%
Student > Bachelor 2 10%
Student > Ph. D. Student 2 10%
Researcher 2 10%
Other 2 10%
Unknown 6 29%
Readers by discipline Count As %
Medicine and Dentistry 7 33%
Nursing and Health Professions 2 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Immunology and Microbiology 1 5%
Business, Management and Accounting 1 5%
Other 2 10%
Unknown 7 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2018.
All research outputs
#2,369,336
of 25,382,440 outputs
Outputs from British Journal of Dermatology
#821
of 9,663 outputs
Outputs of similar age
#46,605
of 341,164 outputs
Outputs of similar age from British Journal of Dermatology
#17
of 153 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,663 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,164 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 153 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.